Ahmed T, Ahmad J. Recent advances in the diagnosis of drug-induced liver injury. World J Hepatol 2024; 16(2): 186-192 [PMID: 38495272 DOI: 10.4254/wjh.v16.i2.186]
Corresponding Author of This Article
Jawad Ahmad, FAASLD, FRCP, MD, Professor, Department of Recanati-Miller Transplantation Institute, Icahn School of Medicine at Mount Sinai, One Gustave L. Levy Place, New York, NY 10029, United States. jawad.ahmad@mountsinai.org
Research Domain of This Article
Gastroenterology & Hepatology
Article-Type of This Article
Minireviews
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Hepatol. Feb 27, 2024; 16(2): 186-192 Published online Feb 27, 2024. doi: 10.4254/wjh.v16.i2.186
Recent advances in the diagnosis of drug-induced liver injury
Taqwa Ahmed, Jawad Ahmad
Taqwa Ahmed, Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, NY 10029, United States
Jawad Ahmad, Department of Recanati-Miller Transplantation Institute, Icahn School of Medicine at Mount Sinai, New York, NY 10029, United States
Author contributions: Ahmed T and Ahmad J contributed equally to this work; All authors have read and approve the final manuscript.
Conflict-of-interest statement: All the authors declare that they have no conflict of interest.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Jawad Ahmad, FAASLD, FRCP, MD, Professor, Department of Recanati-Miller Transplantation Institute, Icahn School of Medicine at Mount Sinai, One Gustave L. Levy Place, New York, NY 10029, United States. jawad.ahmad@mountsinai.org
Received: September 29, 2023 Peer-review started: October 1, 2023 First decision: November 7, 2023 Revised: January 3, 2024 Accepted: February 3, 2024 Article in press: February 3, 2024 Published online: February 27, 2024 Processing time: 150 Days and 21.4 Hours
Abstract
Drug-induced liver injury (DILI) is a major problem in the United States, commonly leading to hospital admission. Diagnosing DILI is difficult as it is a diagnosis of exclusion requiring a temporal relationship between drug exposure and liver injury and a thorough work up for other causes. In addition, DILI has a very variable clinical and histologic presentation that can mimic many different etiologies of liver disease. Objective scoring systems can assess the probability that a drug caused the liver injury but liver biopsy findings are not part of the criteria used in these systems. This review will address some of the recent updates to the scoring systems and the role of liver biopsy in the diagnosis of DILI.
Core Tip: Diagnosing drug induced liver injury (DILI) remains a challenge in the absence of a reliable biomarker. This review highlights some of the recent advances in causality assessment in DILI that will allow clinicians to be more certain in making a diagnosis.
